Floatz Rating
CC43/100
Confidence
Indicative
Sponsor
Fred Hutchinson Cancer Center
Modality
Small molecule
Development Phase
Phase 1
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
28Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT04375631CT.gov CLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic Leukemia | — | Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Acute Undifferentiated Leukemia
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Cladribine (this asset) | Fred Hutchinson Cancer Center | P1 | CC · 43 |
| Fludarabine | Fred Hutchinson Cancer Center | P2 | BB |
| Vincristine Sulfate | M.D. Anderson Cancer Center | P3 | BB |
| Nivestim | Fred Hutchinson Cancer Center | P3 | BB |
| Cytarabine | Fred Hutchinson Cancer Center | P3 | BB |
| Dexasone | Therapeutic Advances in Childhood Leukemia Consortium | P3 | BB |
| Cyclophosphamide | Masonic Cancer Center, University of Minnesota | P3 | BB |
| Etoposide | Syndax Pharmaceuticals | P3 | BB |
| Pegaspargase | Syndax Pharmaceuticals | P3 | BB |
+42 more in the Acute Undifferentiated Leukemia cohort
Other indications for Cladribine
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Relapsing-Remitting Multiple Sclerosis | — | P4 | BBB · 76 |
| Lymphoblastic Lymphoma | — | P4 | BBB · 75 |
| Multiple Sclerosis | — | P4 | BBB · 72 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Cladribine in Acute Undifferentiated Leukemia. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/cladribine-acute-undifferentiated-leukemia
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →